Avacta Group

Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.

Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively and specifically remove established amyloid fibrils.

Bioliberty is a young healthcare technology company that focuses on creating innovative rehabilitation solutions for both degenerative and traumatic conditions.

Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.

R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals with chronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease.

Ternary Therapeutics is a biotechnology research center that specializes in bioinformatics and medicinal chemistry services.

Concert Bio helps businesses create optimal microbial communities.

Theolytics is a biotechnology company in the clinical stage that uses viruses to fight against diseases. Our innovative phenotypic screening Platform allows for the development of effective and targeted candidate treatments, suitable for intravenous delivery and tailored to specific patient groups. Along with progressing our own programs for treating both solid and liquid tumors, we are forming partnerships to further expand and speed up the development of our pipeline.

OutPost Bio aims to unlock new ways to design drugs, ingredients, and consumer health products by boosting its experimental and modelling platforms.

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.

Our jellyfish collagen-based innovation addresses complex regenerative medical needs, shaping next generation treatments and supporting current and future scientific research. At the heart of our products is marine-sourced Collagen Type 0, an evolutionary ancient stem collagen that is foundational, allowing greater applications across multiple indications.

Lario Therapeutics is a company specializing in creating targeted treatment options for epilepsy and neurological conditions.